Vascular Effects of Sitagliptin in Diabetes Mellitus

Status Not yet recruiting

Clinical Trial Summary

Glucagon-like peptide 1 (GLP-1) is a 30-amino acid gut hormone secreted in a nutrient-dependent manner that stimulates insulin secretion and inhibits glucagon secretion and gastric emptying, thereby reducing postprandial glycemia.1,2 GLP-1 is derived from posttranslational proteolysis of preproglucagon, and its peptide sequence is identical in mouse, rat, and human.2,3 After secretion from enteroendocrine L cells, GLP-1(7-36) amide is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) to its N-terminally truncated metabolite GLP-1(9-36), which does not interact with the known GLP-1 receptor.4,5 The diverse actions of GLP-1 include the proliferation, differentiation, and protection from apoptosis of pancreatic β cells and the induction of satiety. GLP-1 also improves memory and learning, stimulates afferent sensory nerves, and has neuroprotective functions.1,6 Furthermore, GLP-1 receptor agonists have been reported to have cardiac and vascular actions in rodents and humans that include effects on contractility, blood pressure, cardiac output,7-10 and cardioprotection.11-14

Clinical Trial Description

The aim of this study is to evaluate the effect of a therapy with the DPP-4-inhibitor sitagliptin on the prognostic relevant endothelial function and endothelial progenitor cells in patients with type 2 diabetes mellitus.

Primary endpoint: Endothelium-dependent vasodilation before and after treatment of patients with type 2 diabetes mellitus with the DPP-4-inhibitor Sitagliptin and placebo treatment respectively.

Secondary endpoint: effect of sitagliptin on mobilization, NO-production and in vivo regenerative capacity of human endothelial progenitor cells before and after treatment of patients with type 2 diabetes mellitus with the DPP-4-inhibitor sitagliptin and placebo treatment respectively ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01096277
Study type	Interventional
Source	Hannover Medical School
Contact	Sajoscha A. Sorrentino, MD
Phone	+49511532
Email	sorrentino.sajoscha@mh-hannover.de
Status	Not yet recruiting
Phase	Phase 4
Start date	October 2010
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02771093` - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus	Phase 4
Completed	`NCT02545842` - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)	Phase 4
Recruiting	`NCT03436212` - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.	N/A
Completed	`NCT03244800` - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.	Phase 2
Completed	`NCT03960424` - Diabetes Management Program for Hispanic/Latino	N/A
Withdrawn	`NCT02769091` - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes	Phase 2
Recruiting	`NCT06065540` - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	Phase 3
Recruiting	`NCT05008276` - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed	`NCT04091373` - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide	Phase 1
Completed	`NCT03296800` - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects	Phase 1
Recruiting	`NCT06212778` - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed	`NCT05979519` - Fresh Carts for Mom's to Improve Food Security and Glucose Management	N/A
Recruiting	`NCT05579314` - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)	Phase 1
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Terminated	`NCT03684642` - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin	Phase 3
Completed	`NCT03248401` - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes	Phase 4
Completed	`NCT03644134` - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns	N/A
Completed	`NCT05295160` - Fasting-Associated Immune-metabolic Remission of Diabetes	N/A
Completed	`NCT02836873` - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment	Phase 3
Completed	`NCT02226003` - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)	Phase 3